Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated aging. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal aging.
Around 150 people worldwide are known to suffer from HGPS, a disease which results from a specific genetic mutation which is not inherited. Usually diagnosed around the age of six months, children with HGPS lose their hair, look old and suffer many of the symptoms of aging, including brittle bones, stroke and heart attacks. They generally live only until their early teens.
In cells from people with HGPS, the nucleus is marked out because, unlike a normal cell’s round nucleus, HGPS cell nuclei are drastically misshapen. Scientists believe this makes the cells more fragile, contributing to HGPS patients’ symptoms.
Proteins called Lamin A and Lamin C play a vital role in nuclear architecture, acting as ‘scaffolding’ for the nucleus. In HGPS, however, mutations in the gene that makes these proteins mean they cannot shape the nucleus correctly.
Working with cells from HGPS patients, researchers from the Wellcome Trust/CRUK Gurdon Institute at the University of Cambridge and the CNRS in France scoured the scientific literature for compounds that might affect nuclear architecture. They then tested a shortlist of the most promising compounds on the cells in the laboratory. Their results are published in the journal Science.
They found that one compound– which they were able to improve, yielding a molecule that they have named Remodelin– effectively improved the damaged nuclei, restoring their shape. Further tests revealed that doing so also improved the health of the cells, making them grow and divide more normally.
The researchers then went on a "fishing trip" to try to work out how the compound worked.
"Most drugs work by binding to something in the cell, so we went fishing. We attached a chemical 'hook' to Remodelin, incubated it with cell extracts, and examined what was attached to it when we reeled it back in," said Dr. Delphine Larrieu of the Gurdon Institute, lead author of the study.
The target they fished out was NAT10, a protein not previously associated with aging or HPGS. “From our following work, we now know that Remodelin works by inhibiting NAT10, so we have gone from finding a potential drug to identifying its target and mechanism-of-action,” Larrieu said.
The results are exciting because few drugs are available to treat HGPS (those that are available only partially improve some of the symptoms and do not extend people’s life span) and because Remodelin works in a different way.
Senior author, Professor Steve Jackson, said: “Remodelin is different because as well as improving the cellular defects, it is the first molecule to also reduce the high level of DNA damage that occurs in these cells, which is believed to contribute to premature aging. What we’re particularly excited about is that Remodelin seems to work in a different way from existing drugs, and has broader effects.”
These findings also improve our understanding of normal aging, because although HGPS is very rare and devastating, it shares many features with normal aging. Moreover, this could open up new treatments for some forms of cancer, because up- or down-regulation of nuclear-lamina proteins has been linked to the aggressiveness of certain cancers.
“This is an example of how basic cell biology can give rise to potential new opportunities for treating human disease, and although our research is focused on one rare disease, we feel that similar approaches could be useful in identifying new treatments for other serious human diseases,” Jackson said.
The next stage of the research, which is already underway, is to see if Remodelin works in animal models of the disease; if it does, the researchers will be able to trial the drug in patients.
Source: University of Cambridge